Medical Technologies

Science Corporation Raises $400 Million to Commercialize Medical Brain-Computer Interface Technology

Science Corporation has successfully raised $400 million in funding to support the commercialization of its "Prima BCI" neural device in Europe and prepare for its launch in the US market to treat vision loss.

2026-11-18
3 min read
8 views
certi.news Editorial Team
Science Corporation Raises $400 Million to Commercialize Medical Brain-Computer Interface Technology

Science Corporation announced the successful closing of a $400 million Series D funding round, aimed at commercializing its brain-computer interface (BCI) system in the European market and preparing for its anticipated launch in the United States of America.

This funding round comes to support expanding the availability of the "Prima BCI" device, which previously obtained the European CE mark and was launched in Europe last July as a treatment for vision loss resulting from retinal diseases. The latest funding round saw participation from a number of prominent investors such as Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, alongside 885 Capital, Y Combinator, and PLC Neurotech, bringing the total funds raised by the company since late last year to approximately $630 million, and over $900 million in its total funding history.

How the Prima Vision Restoration System Works

The Prima medical system consists of a subretinal implant and glasses equipped with a micro-camera. The camera captures and processes images, then projects them onto the implant using near-infrared light. Once the implant is stimulated by these rays, it stimulates the neural cells in the retina, which in turn process the information and send it directly to the brain to restore central vision.

The system has proven its effectiveness in clinical trials involving 38 patients suffering from geographic atrophy, where the majority of participants regained the ability to read 10 or more letters in vision tests, and these positive improvements continued for a follow-up period of 36 months.

Expansion in Europe and Regulatory Plans in America

Following its receipt of the European CE approval, the company began submitting applications for national reimbursement in European countries and activating clinical sites, with Germany designated as the first destination to perform the initial commercial system implants.

Around the same time as the European launch, the US Food and Drug Administration (FDA) granted the Prima device two Humanitarian Use Device (HUD) designations, covering patients who have lost their vision due to advanced geographic atrophy or Stargardt disease, paving the way to submit the final approval application via the Humanitarian Device Exemption (HDE) pathway.

What Changes Practically?

The company will allocate a significant portion of the new funding round's money to pursue US Food and Drug Administration approval through the humanitarian exemption pathway, alongside expanding research, operations, and manufacturing infrastructure.

The company has also allocated a major investment to develop its biohybrid program, which aims to develop a neural interface technology using living neurons to communicate with the brain, potentially avoiding the risks and limitations associated with introducing traditional wires and metal parts directly into human tissue.

News source
c
Author

certi.news Editorial Team

In the same category

You may also like

View all news